Wellington Management Group
SAGE

Wellington Management Group’s Sage Therapeutics SAGE Stock Holding History

Wellington Management Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39,645
Closed -$431K – 2012
2024
Q2 		$431K Sell
39,645
-4,712,552
-99% -$60.4M ﹤0.01% 1791
2024
Q1 		$89.1M Sell
4,752,197
-1,309,799
-22% -$30.2M 0.02% 585
2023
Q4 		$131M Sell
6,061,996
-510,264
-8% -$10.1M 0.02% 500
2023
Q3 		$135M Buy
6,572,260
+208,630
+3% +$6.03M 0.03% 450
2023
Q2 		$299M Buy
6,363,630
+649,207
+11% +$32.3M 0.06% 305
2023
Q1 		$240M Buy
5,714,423
+198,287
+4% +$8.53M 0.05% 351
2022
Q4 		$210M Buy
5,516,136
+583,618
+12% +$22.3M 0.04% 375
2022
Q3 		$193M Buy
4,932,518
+182,895
+4% +$7.07M 0.04% 376
2022
Q2 		$153M Sell
4,749,623
-2,245,377
-32% -$75.3M 0.03% 440
2022
Q1 		$232M Sell
6,995,000
-131,411
-2% -$4.94M 0.04% 381
2021
Q4 		$303M Buy
7,126,411
+356,478
+5% +$14.9M 0.05% 339
2021
Q3 		$300M Buy
6,769,933
+957,993
+16% +$43.9M 0.05% 345
2021
Q2 		$330M Buy
5,811,940
+646,151
+13% +$45.7M 0.06% 317
2021
Q1 		$387M Buy
5,165,789
+882,160
+21% +$72.3M 0.07% 281
2020
Q4 		$371M Buy
4,283,629
+4,045,121
+1,696% +$298M 0.07% 269
2020
Q3 		$14.6M Buy
238,508
+94,161
+65% +$4.77M ﹤0.01% 1017
2020
Q2 		$6M Buy
+144,347
New +$5.24M ﹤0.01% 1178
2020
Q1 		– Sell
-975,613
Closed -$70.4M – 2024
2019
Q4 		$70.4M Sell
975,613
-1,013,614
-51% -$125M 0.01% 670
2019
Q3 		$279M Sell
1,989,227
-200,445
-9% -$33.5M 0.06% 293
2019
Q2 		$401M Sell
2,189,672
-17,689
-0.8% -$3.02M 0.09% 233
2019
Q1 		$351M Buy
2,207,361
+285,526
+15% +$41.3M 0.08% 246
2018
Q4 		$184M Sell
1,921,835
-48,935
-2% -$5.6M 0.05% 359
2018
Q3 		$278M Sell
1,970,770
-10,734
-0.5% -$1.66M 0.06% 314
2018
Q2 		$310M Sell
1,981,504
-287,018
-13% -$45.1M 0.07% 287
2018
Q1 		$365M Buy
2,268,522
+199,517
+10% +$33.9M 0.08% 252
2017
Q4 		$341M Buy
2,069,005
+369,796
+22% +$35.9M 0.08% 256
2017
Q3 		$106M Buy
1,699,209
+114,760
+7% +$9.01M 0.02% 530
2017
Q2 		$126M Buy
+1,584,449
New +$115M 0.03% 446

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wellington Management Group's SAGE Position: Q3 2024 in Review

Wellington Management Group sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 39,645 shares — an estimated $431K sold.

Wellington Management Group first reported a position in SAGE in Q2 2017 and held it in 28 quarters. The position peaked at $401M in Q2 2019. 175 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • Wellington Management Group reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Wellington Management Group sold 39,645 Sage Therapeutics shares in Q3 2024, an estimated $431K.
  • Wellington Management Group first reported a position in Sage Therapeutics in Q2 2017 and held it in 28 quarters.
  • Wellington Management Group's Sage Therapeutics position peaked at $401M in Q2 2019.
  • 175 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Wellington Management Group's 13F filing for Q3 2024, filed 14 Nov 2024.